Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine.

Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine.
复制标题

新型 ATR-AP205-001 结合抗高血压疫苗的免疫反应。

DOI:
10.1038/s41598-017-12996-y
复制
发表时间:
2017-10-03
期刊:
影响因子:
4.6
通讯作者:
Liao Y
Liao Y
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Hu X;Deng Y;Chen X;Zhou Y;Zhang H;Wu H;Yang S;Chen F;Zhou Z;Wang M;Qiu Z;Liao Y

文献摘要

参考文献

被引文献

相似文献

我们研发了一种基于病毒样颗粒(VLP)的抗1型血管紧张素II受体治疗性疫苗ATR - AP205 - 001,它能显著降低血压并保护高血压动物的靶器官。在本研究中,我们重点关注了这种基于VLP的疫苗的免疫效果和安全性。通过与解聚的二聚体疫苗ATR - Dimer - 001进行对比,我们发现ATR - AP205 - 001在给药后不久便抵达淋巴结的被膜下窦,随后通过滤泡B细胞转运在滤泡树突状细胞上聚集,而ATR - Dimer - 001疫苗则与滤泡树突状细胞无关联。ATR - AP205 - 001疫苗能强烈激活树突状细胞,进而促进T细胞分化为滤泡辅助性T细胞。ATR - AP205 - 001疫苗可诱导强烈的生发中心反应,这转化为特异性抗体产生的增强以及持久的B细胞记忆,其效果远优于ATR - Dimer - 001疫苗。此外,与ATR - Dimer - 001疫苗类似,在ATR - AP205 - 001疫苗中未观察到细胞毒性T细胞或Th1/Th17细胞介导的炎症反应。我们得出结论,ATR - AP205 - 001疫苗通过B细胞、滤泡树突状细胞和滤泡辅助性T细胞的协同作用,迅速诱导出强大的体液免疫,为未来高血压的临床干预提供了一种有效且安全的手段。
We developed a virus-like particle (VLP)-based therapeutic vaccine against angiotensin II receptor type 1, ATR-AP205-001, which could significantly reduce the blood pressure and protect target organs of hypertensive animals. In this study, we focused on the immunological effect and safety of the VLP-based vaccine. By comparing to the depolymerized dimeric vaccine ATR-Dimer-001, we found that ATR-AP205-001 reached subcapsular sinus of lymph node shortly after administration, followed by accumulation on follicle dendritic cells via follicle B cell transportation, while ATR-Dimer-001 vaccine showed no association with FDCs. ATR-AP205-001 vaccine strongly activated dendritic cells, which promoted T cells differentiation to follicular helper T cells. ATR-AP205-001 vaccine induced powerful germinal center reaction, which was translated to a boost of specific antibody production and long-lasting B cell memory, far superior to ATR-Dimer-001 vaccine. Moreover, neither cytotoxic T cells, nor Th1/Th17 cell-mediated inflammation was observed in ATR-AP205-001 vaccine, similar to ATR-Dimer-001 vaccine. We concluded that ATR-AP205-001 vaccine quickly induced potent humoral immunity through collaboration of B cells, follicular dendritic cells and follicular helper T cells, providing an effective and safe intervention for hypertension in the future clinical application.
1 型血管紧张素受体疫苗可预防链脲佐菌素诱发的糖尿病肾病
DOI: 10.1007/s00109-015-1343-6
发表时间: 2016-02
期刊: Journal of molecular medicine (Berlin, Germany)
影响因子: --
作者:
Ding D;Du Y;Qiu Z;Yan S;Chen F;Wang M;Yang S;Zhou Y;Hu X;Deng Y;Wang S;Wang L;Zhang H;Wu H;Yu X;Zhou Z;Liao Y;Chen X
通讯作者: Chen X
DOI: 10.1126/science.1176676
发表时间: 2009-08-21
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Nurieva RI;Chung Y;Martinez GJ;Yang XO;Tanaka S;Matskevitch TD;Wang YH;Dong C
通讯作者: Dong C
DOI: 10.1073/pnas.1112648109
发表时间: 2012-01-24
影响因子: 11.1
作者:
Moon, James J.;Suh, Heikyung;Irvine, Darrell J.
通讯作者: Irvine, Darrell J.
DOI: 10.1038/srep03775
发表时间: 2014-01-20
期刊: Scientific reports
影响因子: 4.6
作者:
Phanse Y;Carrillo-Conde BR;Ramer-Tait AE;Broderick S;Kong CS;Rajan K;Flick R;Mandell RB;Narasimhan B;Wannemuehler MJ
通讯作者: Wannemuehler MJ
早期的BCR事件和B细胞上MHC II类上的抗原捕获,加工和加载。
DOI: 10.3389/fimmu.2014.00092
发表时间: 2014
影响因子: 7.3
作者:
Avalos AM;Ploegh HL
通讯作者: Ploegh HL